Abstract
Purpose
The aim of this study was to analyse the utilization patterns of drugs acting on the nervous system in the Republic of Srpska, Bosnia & Herzegovina between 2002 and 2008.
Methods
This was a retrospective study aimed at analysing outpatient utilization of drugs reimbursed by the Health Insurance Fund, with a focus on the utilization of drugs acting on the nervous system. Anatomical therapeutic chemical/defined daily dose methodology was used to monitor drug utilization, and the drug utilization 90% (DU90%) method was used to assess drug prescribing.
Results
The most highly used drug subgroups were psycholeptics and antiepileptics followed by the psychoanaleptics. Anxyolitics comprised the most prescribed pharmacological subgroup over the whole study period, but a decrease was observed in 2007 and 2008. Following updating of the list with selective serotonin re-uptake inhibitor drugs, particularly sertraline, antidepressant use increased fivefold in 2008 compared to 2006. Tramadol was the predominant opioid analgesics in terms of utilization, while the use of oral morphine was low. Diazepam was the most highly prescribed drug, followed by phenobarbital and carbamazepine. The list update with the new generation drugs was immediately reflected in the DU90% profile.
Conclusions
The observed tendency toward increased total drug utilization observed in our study is comparable to worldwide trends. Implementation of new clinical guidelines for nervous diseases and updating of the list of reimbursable drugs with the addition of new ones contributed to the observed improvement in prescribing patterns in primary healthcare during the study period. The DU90% is shown to be a simple rough method for assessing prescribing quality. More stratified analyses should be performed on a routine basis to ensure a rational use of medicines and a cost-efficient use of limited healthcare resources.
Similar content being viewed by others
References
Smith G (2003) Drug prescribers and pharmaceutical carers in integrated health care. Pharm J 271:380–383
World Health Organization (2004) Atlas: country resources for neurological disorders. WHO, Geneva
World Health Organization (2006) Neurology and public health—facts. Available at: http://www.who.int/mental_health/neurology/en/index.html Accessed 1 May 2009
World Health Organization (2001) Preventing suffering and death from mental disorders: European perspectives. The world health report. Press release EURO 11. WHO, Copenhagen
World Health Organization (2003) Investing in mental health. WHO, Geneva. Available at: http://www.who.int/mental_health/media/investing_mnh.pdf. Accessed 25 May 2009
Intercontinental Marketing Service (2004) Global pharmaceutical sales grew 7 percent to $550 billion. Available at: http://www.imshealth.com Accessed 1 May 2009
Intercontinental Marketing Service (2007) Top 10 global therapeutic classes. Available via http://www.imshealth.com. Accessed 13 May 2009
Marković Peković V (2008) Pharmacoepidemiological analyses of reimbursable medicines consumption over 2002-2006. PhD thesis. University of Banja Luka, Banja Luka
Marković Peković V, Škrbić R, Stoisavljević Šatara S (2009) Utilisation of cardiovascular medicines in Republic of Srpska, Bosnia & Herzegovina, five years study. Pharmacoepidemiol Drug Saf 18(6):320–326. doi:10.1002/pds.1704
Republika Srpska Institute of Statistics (2008) Republika Srpska in figures. Institute of Statistics, Banja Luka
Republika Srpska Institute of Statistics (2006) Demographic Statistical Bulletin No11. Institute of Statistics, Banja Luka
The Republic of Srpska Government (2006) Economic politics. Government of the Republic of Srpska, Banja Luka
The Republic of Srpska Government (2008) Economic politics. Government of the Republic of Srpska, Banja Luka
WHO Collaborating Centre for Drug Statistics Methodology (2005) ATC/DDD index. WHO Collaborating Centre, Oslo. Available at: http://www.whocc.no/atcddd/ Accessed 13 Jan 2009
Jakovljević V, Stanulović M, Sabo A, Mikov M (2000) ATC classification of medicines with DDDs for medicines on the market. OrtoMedics, Novi Sad
Škrbić R, Marković Peković V, Stoisavljević Šatara S, Babić Đurić D (2001) ATC classification of medicines and monitoring of consumption of medicines with DDD methodology for medicines with marketing authorisation in Republika Srpska. School of Medicine, Banja Luka
Bergman U, Popa C, Thomson Y, Wettermark B, Einarson TR, Aberg H et al (1998) Drug utilization 90%—a simple method for assessing the quality of drug prescribing. Eur J Clin Pharmacol 54(2):113–118
Wettermark B, Pehrsson A, Jinnerot D, Berman U (2003) Drug utilization 90% profiles—a useful tool for quality prescribing in primary health care in Stockholm. Pharmacoepidemiol Drug Saf 12(6):499–510
Agency for Medicinal Products and Medical Devices Republic of Croatia (2004) Medicines consumption. Available at: http://www.almp.hr/?ln=hr&w=publikacije&d=promet_lijekova_2004 Accessed 13 May 2009
Agency for Medicinal Products and Medical Devices Republic of Croatia (2005) Medicines consumption. Available at: http://www.almp.hr/?ln=hr&w=publikacije&d=promet_lijekova_2005 Accessed 13 May 2009
Agency for Medicinal Products and Medical Devices of the Republic of Croatia (2006) Medicines consumption. Available at: http://www.almp.hr/?ln=hr&w=publikacije&d=promet_lijekova_2006 Accessed 13 May 2009
Medicines and Medical Devices Agency of Serbia (2006) Consumption of medicines 2004/2005. Medicines and Medical Devices Agency, Belgrade
Medicines and Medical Devices Agency of Serbia (2007) Consumption of medicines 2007. Medicines and Medical Devices Agency, Belgrade
Montenegro Health Insurance Fund (2006) Outpatient consumption of medicines in 2005. Montenegro Health Insurance Fund, Podgorica
Montenegro Health Insurance Fund (2008) Outpatient consumption of medicines in 2007. Montenegro Health Insurance Fund, Podgorica
Nordic Medico Statistical Committee (2004) Medicines Consumption in the Nordic Countries 1999–2003. Available at: http://www.nom-nos.dk/Medicinebook/medicines. Accessed 15 May 2009
Norwegian Institute for Public Health (2009) Drug Consumption in Norway 2004–2008. Available at: http://www.legemiddelforbruk.no/english/ Accessed 14 June 2009
The Norwegian Association of Pharmaceutical Manufacturers (2006) Facts and Figures. Available at: http://www.legemiddelstatistikk.com/tf/2006/files/english/about_lmi.html. Accessed 15 May 2009
National Agency for Medicines Finland (2008) Drug consumption in years 2004–2007. Available at: http://www.nam.fi/medicines/drug_consumption Accessed 10 Apr 2007
National Agency for Medicines Finland (2008) Drug consumption in 2008. Available at: http://www.nam.fi/medicines/drug_consumption Accessed 10 Apr 2009
Ministero della Salute Osservatorio Nazionale sull’Impiego dei Medicinali (2007) L’uso dei Farmaci in Italia. Available at: http://www.agenziafarmaco.it/allegati/rapporto_osmed_2007.pdf. Accessed 15 May 2009
Australian Institute of Health and Welfare (2003) Statistics on drug use in Australia in 2002. Cat. no PHE 4. Available at: http://www.aihw.gov.au/publications/phe/sdua02-c05.pdf Accessed 1 Feb 2008
Australian Institute of Health and Welfare (2008) Australia’s health no. 11. Available at: http://www.aihw.gov.au/publications/aus/ah08/ah08.pdf. Accessed 14 May 2009
Danish Medicines Agency (2008) Medicinal products Statistics in Denmark 2003–2007. Available at: http://www.dkma.dk/db/filarkiv/6692/Kapitel2.pdf Accessed 10 Apr 2009
Vrhovac B, Aganović I, Anić B, Barbarić-Babić V, Bakran I, Barić I et al (2003) Pharmacotherapeutical Manual, 4th edn. Medicinska naklada, Zagreb
Del Rio MC, Alvarez FJ (1996) How benzodiazepines are prescribed in primary health care settings in Spain. Therapie 51:185–189
Van Hulten R, Isacson D, Bakker A et al (2003) Comparing patterns of long-term benzodiazepine use between Dutch and Swedish community. Pharmacoepidemiol Drug Saf 12:49–53. doi:10.1002/pds.784
Grigoryan L, Haaijer-Ruskamp FM, Burgerdorf JGM, Mechtler R, Deschepper R, Tambic-Andrasevic A et al (2006) Self-medication with antimicrobial drugs in Europe. Emerg Infect Dis 12:452–459
Divac N, Jašović M, Đukić LJ, Vujnović M, Babić D, Bajčetić M et al (2004) Benzodiazepines utilization and self medication as correlates of stress in the population of Serbia. Pharmacoepidemiol Drug Saf 13:315–322. doi:10.1002/pds.940
Divac N (2004) Pharmacoepidemiological analysis of psychopharmaca in primary health care. PhD thesis. University of Belgrade, Belgrade
Štimac D, Vukušić I, Čulig J, Šostar Z (2007) Comparision of outpatient utilization of psychopharmaceuticals between Croatia and Scandinavian countries (2001–2003). Med Glas 4:14–20
Ciuna A, Andretta M, Corbari L, Levi D, Mirandola M, Sorio A et al (2004) Are we going to increase the use of antidepressants up to that of benzodiazepines? Eur J Clin Pharmacol 60(9):629–634
Fürst J, Kocmur M (2003) Use of psychiatric drugs in Slovenia comparision to Scandinavian countries. Pharmacoepidemiol Drug Saf 12:399–403. doi:10.1002/pds.826
Ministry of Health and Social Welfare of the Republic of Srpska (2004) Guidelines for nervous diseases: Distimia. Ministry of Health and Social Welfare of the Republic of Srpska, Banja Luka
Ministry of Health and Social Welfare of the Republic of Srpska (2004) Guidelines for nervous diseases: anxious disorders. Ministry of Health and Social Welfare of the Republic of Srpska, Banja Luka
Ministry of Health and Social Welfare of the Republic of Srpska (2004) Guidelines for nervous diseases: depression and bipolar disorder. Ministry of Health and Social Welfare of the Republic of Srpska, Banja Luka
Pérez J, Marín N, Vallano A, Castells X, Capellà D (2005) Consumption and cost of antipsychotic drugs. Actas Esp Psiquiatr 33(2):110–116
Grohol JM (2006) Schizophrenia Treatment. Available at: http://www.psychcentral.com/disorders/sx31t.htm. Accessed 25 May 2009
Leucht S, Corves C, Arbter RR, Li C, Davis JM (2009) Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 373(9657):31–41
Hajak G, Műller WE, Wittchen HU, Pittrow D, Kirch W (2003) Abuse and dependence potential for the non-benzodiazepine hypnotics zolpidem and zopiclone: a review of case reports and epidemiological data. Addiction 98(10):1371–1378
Hoffmann F, Pfannkuche M, Glaeske G (2008) High use of zolpidem and zopiclone. Cross-sectional study using claims data. Nervenarzt 79(1):67–72
Prpić I, Paučić-Kirinčić E, Vlahović-Palčevski V (2001) Utilization of antiepileptic drugs in clinical centre Rijeka. Pharmaca 39:147–169
Paučić-Kirinčić E, Prpić I, Sasso A, Gazdik M, Modrušan-Mozetić Z, Vlahović-Palčevski V (2002) Antiepileptic drugs for the treatment of epilepsy and epileptics syndrome in childhood. Paediatr Croat 46:187–191
Freely M (1999) Drug treatment of epilepsy. Br Med J 318:106–109
Hudec R, Brozeková L, Foltán V, Tisonová J, Kriska M (2009) 5 most consumed opioid analgesics in Slovakia in the year 2006-comparision to five other countries (Finland, Norway, Denmark, Spain, Australia). Bratisl Lek Listy 110(5):316–318
Garcia del Poso J, Carvajal A, Viloria JM, Velasco A, Garcia del Poso V (2008) Trends in the consumption of opioid analgesics in Spain. Higher increases as fentanyl replaces morphine. Eur J Clin Pharmacol 64(4):411–415. doi:10.1007/s00228-007-0419-9
Hamunen K, Paakkari P, Kalso E (2008) Trends in opioid consumption in the Nordic countries 2002–2006. Eur J Pain. doi:10.1016/j.ejpain.2008.11.006
Hudec R, Tisonová J, Brozeková L, Foltán V (2004) Trends in consumption of opioid analgesic in Slovak Republic during 1998–2002. Eur J Clin Pharmacol 60(6):445–448
De Conno F, Ripamonti C, Brunelli C (2005) Opioid purchases and expenditures in nine western European countries:“Are we killing of morphine?”. Palliat Med 19(3):179–184. doi:10.1191/0269216305pm1002oa
Štimac D, Čulig J (2009) Outpatient utilization of psychopharmaceuticals in the city of Zagreb. Psychiatr Danub 21(1):56–64
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Marković-Peković, V., Stoisavljević-Šatara, S. & Škrbić, R. Outpatient utilization of drugs acting on nervous system: a study from the Republic of Srpska, Bosnia & Herzegovina. Eur J Clin Pharmacol 66, 177–186 (2010). https://doi.org/10.1007/s00228-009-0732-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00228-009-0732-6